Eli Lilly and Company
Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.
DitchCarbon Score
How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eli Lilly and Company's score of 36 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eli Lilly and Company's reported carbon emissions
In 2023, Eli Lilly and Company reported total carbon emissions of approximately 5,131,000,000 kg CO2e, with emissions distributed across various scopes: 182,000,000 kg CO2e (Scope 1), 345,000,000 kg CO2e (Scope 2), and a significant 5,139,500,000 kg CO2e (Scope 3). The company has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. Historically, Eli Lilly's emissions have shown fluctuations, with Scope 1 emissions decreasing from 527,000,000 kg CO2e in 2007 to 182,000,000 kg CO2e in 2023. Scope 2 emissions also decreased from 1,310,000,000 kg CO2e in 2007 to 345,000,000 kg CO2e in 2023. However, Scope 3 emissions have increased significantly, indicating a need for enhanced focus on upstream and downstream activities. Eli Lilly's climate commitments align with industry standards, reflecting a growing awareness of the importance of sustainability in the pharmaceutical sector. The company continues to explore strategies to mitigate its environmental impact, although detailed reduction targets remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 527,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 14,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eli Lilly and Company is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
